BioPharmSignal logoBioPharmSignal

Biotech News

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

Tarsus Pharmaceuticals (TARS)Tarsus PharmaceuticalsEarnings

IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, May 6, 2026 to report its first quarter 2026 financial results and provide a corporate update.

Related news

TARSTarsus Pharmaceuticals2026-05-06 20:05 EST

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

IRIXIRIDEX2026-05-05 20:05 EST

Iridex to Report First Quarter 2026 Financial Results on May 19, 2026

LCTXLineage Cell Therapeutics2026-05-05 12:00 EST

Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026

LENZLenz Therapeutics Inc2026-05-04 12:00 EST

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

EYPTEyePoint Pharmaceuticals2026-04-29 11:00 EST

EyePoint to Report First Quarter 2026 Financial Results on May 6, 2026

OCULOcular Therapeutix2026-04-28 11:00 EST

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026

HROWHarrow, Inc.2026-04-27 11:00 EST

Harrow To Report First Quarter 2026 Financial Results After Market Close on May 11, 2026

SGHTSight Sciences2026-04-21 20:05 EST

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

BLTEBelite Bio2026-05-13 20:00 EST

Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results

View all latest news

Tarsus Pharmaceuticals

Eye-Care Therapeutics Tarsus Pharmaceuticals develops and commercializes medicines that target underlying causes of eye disease, using the antiparasitic agent lotilaner across multiple formulations and indications. XDEMVY XDEMVY is an ophthalmic lotilaner solution approved for Demodex blepharitis. It eradicates Demodex mites through a...

Recent company news

TARSTarsus Pharmaceuticals2026-08-06 11:03 EST

Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth

TARSTarsus Pharmaceuticals2026-08-06 11:02 EST

Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing

TARSTarsus Pharmaceuticals2026-08-06 11:01 EST

Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position

TARSTarsus Pharmaceuticals2026-08-06 00:03 EST

Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

TARSTarsus Pharmaceuticals2026-07-13 20:05 EST

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Stock data

Close
65.33 USD
Market cap
2.47B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States